Myelofibrosis is a progressive, relentless, debilitating disease1
Splenomegaly and myelofibrosis symptoms present a significant disease burden2
- MF is a serious haematologic malignancy with a median survival range of only 2 to 4 years in intermediate-2 and high-risk patients3
- Worsening, debilitating disease-related symptoms compromise QoL2,4
- More than 80% of MF patients experience splenomegaly5,6
JAK dysregulation underlies MF and its clinical manifestations1,2

Adapted from: Mesa RA et al. Haematologica. 2014;99(2):292-298. Verstovsek S et al. N Engl J Med. 2010;363(12):1117-1127.1,2
Myelofibrosis is a life-threatening and debilitating haematologic malignancy3